RxDoctor Payments Data

Leonard Sanders, MD

Endocrinology, Diabetes & Metabolism · Monterey, CANPI 1336160613

Payments from drug & device makers

$18,136in general payments, 2019–2025

Across 117 payments — averaging $155.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$15K
  • Insulet Corporation$1K
  • Abbott$388
  • BETA Bionics, Inc.$380
  • AstraZeneca$211
  • Lilly USA, LLC$174
  • plus $654 from 11 others

What the payments were for

  • Speaking & faculty fees$10,50058%
  • Travel & lodging$4,45125%
  • Food & beverage$3,15017%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,136 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.

See all endocrinology, diabetes & metabolism providers in California

Medicare billing

Part B allowed, 2024
$109,809
Medicare patients
240
Services billed
791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide319$427,384
TrulicityDulaglutide250$291,022
JardianceEmpagliflozin182$268,619
OzempicSemaglutide45$50,172
TymlosAbaloparatide13$33,750
Repatha SureclickEvolocumab31$27,865
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$23,002
ProliaDenosumab12$19,740
JanuviaSitagliptin Phosphate18$19,186
Semglee (Yfgn) PenInsulin Glargine-Yfgn19$17,832
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$14,084
TradjentaLinagliptin12$13,787
Fiasp FlextouchInsulin Aspart (Niacinamide)19$12,606
Nano 2nd Gen Pen NeedlePen Needle, Diabetic58$7,015
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$174$718,406569 claims
Novo NordiskOzempic$43$50,17245 claims
Radius Health, Inc.Tymlos$15$33,75013 claims
AmgenProlia$169$19,74012 claims
MerckJanuvia$15,171$19,18618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.

Other endocrinology, diabetes & metabolism in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →